Medskin Solutions Dr. Suwelac AG announced FDA FDA (k) clearance for its flagship med care product portfolio MatriDerm®.
Hamburg, Germany, Jan 11, 2021 / PRNewswire / – MatriDerm® is a single-use three-dimensional acellular dermal matrix composed of bovine collagen fibers and bovine elastin. MatriDerm® is indicated for use in the management of full thickness and partial lesions. The technology has reviewed more than 150 peer-published articles and is currently sold to treat more than 300,000 patients worldwide.
“We are pleased to receive 510 (k) clearance for our unique MatriDerm® products. This important milestone is Medskin Solutions Dr. Represents our commitment at Suvelac, which is said to bring innovation and differentiated technologies to healthcare professionals and patients around the world.
“As we cross Europe, To Middle East, Asia, And Latin america Our focus will be to educate and support health professionals and our partners, as we commercialize MatriDerm® in the largest medical device market globally. Jason Gugliazza, Vice President Med Care Division.
Medskin Solutions Dr. Suvelac AG is a GermanySkilled expert in biotech solutions for tissue regeneration and skin health. Our technical core competence is our proprietary Advanced CryoSafe ™ method that allows us to maintain and refine the response to bioactive substances. Our science-based solutions create effective and easily used treatments that provide added value and serve patients and physicians alike. For our customers, we develop the most effective, targeted and cost-effective solutions in regenerative medicine, advanced wound care and professional skin care.
Content is by PR Newswire. Tech Media is not responsible for the content provided or any link related to this content. Tech Media is not responsible for the accuracy, timeliness or quality of content.